Insider Transactions in Q2 2021 at Exelixis, Inc. (EXEL)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 17
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
SELL
Open market or private sale
|
Direct |
60,000
-13.35%
|
$1,320,000
$22.18 P/Share
|
|
Jun 17
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+11.78%
|
$60,000
$1.9 P/Share
|
|
May 27
2021
|
Julie Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,424
+33.42%
|
-
|
|
May 27
2021
|
George Poste Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,424
+8.64%
|
-
|
|
May 27
2021
|
Maria C Freire Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,299
+17.14%
|
-
|
|
May 27
2021
|
Stelios Papadopoulos Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,424
+1.24%
|
-
|
|
May 27
2021
|
Vincent T Marchesi Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,299
+10.03%
|
-
|
|
May 27
2021
|
Jack L Wyszomierski Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,299
+3.34%
|
-
|
|
May 18
2021
|
Patrick J. Haley EVP, Commercial |
SELL
Open market or private sale
|
Direct |
14,593
-4.94%
|
$350,232
$24.73 P/Share
|
|
May 17
2021
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
18,000
-2.89%
|
$450,000
$25.39 P/Share
|
|
May 15
2021
|
Patrick J. Haley EVP, Commercial |
SELL
Payment of exercise price or tax liability
|
Direct |
3,026
-1.01%
|
$75,650
$25.56 P/Share
|
|
May 14
2021
|
George Poste Director |
SELL
Open market or private sale
|
Direct |
40,802
-20.61%
|
$979,248
$24.97 P/Share
|
|
May 14
2021
|
Vincent T Marchesi Director |
SELL
Open market or private sale
|
Direct |
40,000
-37.7%
|
$1,000,000
$25.04 P/Share
|
|
May 14
2021
|
Vincent T Marchesi Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+27.38%
|
$240,000
$6.3 P/Share
|
|
May 14
2021
|
Michael Morrissey President and CEO |
BUY
Bona fide gift
|
Indirect |
19,722
+1.86%
|
-
|
|
May 14
2021
|
Michael Morrissey President and CEO |
SELL
Bona fide gift
|
Direct |
19,722
-3.86%
|
-
|
|
May 13
2021
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
SELL
Open market or private sale
|
Direct |
100,000
-14.0%
|
$2,500,000
$25.38 P/Share
|
|
May 13
2021
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+12.28%
|
$100,000
$1.9 P/Share
|
|
May 12
2021
|
Michael Morrissey President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
30,278
-5.59%
|
$756,950
$25.16 P/Share
|
|
May 12
2021
|
Michael Morrissey President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+8.45%
|
$200,000
$4.2 P/Share
|
|
May 11
2021
|
Maria C Freire Director |
SELL
Open market or private sale
|
Direct |
8,275
-20.63%
|
$206,875
$25.01 P/Share
|
|
May 11
2021
|
Stelios Papadopoulos Director |
SELL
Open market or private sale
|
Direct |
20,770
-0.55%
|
$498,480
$24.99 P/Share
|
|
May 11
2021
|
Stelios Papadopoulos Director |
BUY
Exercise of conversion of derivative security
|
Direct |
120,000
+3.08%
|
$480,000
$4.27 P/Share
|
|
May 10
2021
|
Michael Morrissey President and CEO |
SELL
Bona fide gift
|
Indirect |
40,616
-3.83%
|
-
|
|
Apr 26
2021
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
18,000
-2.79%
|
$450,000
$25.03 P/Share
|
|
Apr 26
2021
|
Patrick J. Haley EVP, Commercial |
SELL
Open market or private sale
|
Direct |
7,665
-2.51%
|
$191,625
$25.03 P/Share
|
|
Apr 26
2021
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
SELL
Open market or private sale
|
Direct |
50,000
-7.54%
|
$1,250,000
$25.0 P/Share
|
|
Apr 26
2021
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+7.01%
|
$50,000
$1.7 P/Share
|
|
Apr 01
2021
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
SELL
Open market or private sale
|
Direct |
50,000
-7.54%
|
$1,150,000
$23.0 P/Share
|
|
Apr 01
2021
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+7.01%
|
$50,000
$1.7 P/Share
|
|
Apr 01
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
SELL
Open market or private sale
|
Direct |
60,000
-13.35%
|
$1,320,000
$22.96 P/Share
|
|
Apr 01
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+11.78%
|
$60,000
$1.7 P/Share
|